Losartan Market to Reach USD 2.3 Billion by 2034, Driven by Rising Hypertension and Prefrail Geriatric Population at 4.0% CAGR

The global losartan market was valued at US$ 1.5 Bn in 2023 and is expected to grow at a CAGR of 4.0% from 2024 to 2034, reaching US$ 2.3 Bn by the end of 2034. Market growth is primarily driven by the increasing incidence of hypertension and the rise in the prefrail geriatric population.

Losartan is an angiotensin II receptor blocker (ARB) used alone or in combination with other medicines to treat hypertension. It is also used to reduce the risk of stroke in individuals with high blood pressure and left ventricular hypertrophy. The drug is prescribed for certain patients with kidney problems and those with a history of hypertension and type 2 diabetes.

Growing awareness regarding hypertension management and the therapeutic benefits of losartan is contributing to demand across several regions. Companies operating in the market are also exploring additional therapeutic applications of losartan, including its potential role in combination chemo-immunotherapy for triple-negative breast cancer and in reducing chronic kidney disease and mortality following acute kidney injury.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86266

Losartan Market Overview

Hypertension places additional workload on the arteries and heart. When elevated blood pressure persists for an extended period, it can adversely affect the functioning of the cardiovascular system and damage blood vessels in the kidneys, heart, and brain. Such complications can contribute to heart failure, stroke, or kidney failure.

Losartan works by blocking the action of a substance that causes blood vessels to tighten. As an ARB, it helps relax blood vessels and lower blood pressure, thereby making it easier for the heart to pump blood around the body. This mechanism supports its use in the management of hypertension and associated cardiovascular risks.

Losartan is also prescribed to individuals with certain kidney problems, particularly patients with a history of hypertension and type 2 diabetes. The medicine requires a doctor's prescription, supporting controlled and medically supervised use.

The increasing incidence of hypertension, growing geriatric population, and rising awareness of blood pressure management are creating a favorable environment for the losartan market. In addition, ongoing research into expanded therapeutic applications is creating further opportunities for market participants.

Rise in Prefrail Geriatric Population Fueling Losartan Market Growth

The increase in the prefrail geriatric population is emerging as an important factor driving demand for losartan. Prefrail older adults are considered vulnerable to several adverse health outcomes, including functional decline, falls, disability, and early mortality.

Research conducted by investigators at McGovern Medical School at UTHealth Houston has indicated that losartan, a commonly used blood pressure medication, may improve measures associated with frailty among prefrail older adults. The study reported reductions in frailty scores among patients receiving losartan, along with improvements in physical function.

The research also identified changes at the molecular level among patients in the losartan group. Stress markers and metabolism were reported to show positive changes, further supporting research interest in the potential effects of the medicine beyond blood pressure control.

The growing number of prefrail older adults is therefore expected to contribute to the expansion of the losartan market. As healthcare systems increasingly focus on maintaining physical function and managing age-associated health risks, demand for established therapies used in older populations is likely to remain important.

Rising Incidence of Hypertension Driving Demand for Losartan

The growing prevalence of hypertension worldwide represents a major growth driver for the losartan market. Losartan is used in patients with hypertension and left ventricular hypertrophy, where it inhibits angiotensin II-induced cardiac remodeling and helps reduce the risk of stroke.

By relaxing and broadening blood vessels, losartan lowers blood pressure and reduces the effort required by the heart to pump blood throughout the body. Its established role in hypertension management makes the drug relevant to the expanding global population affected by elevated blood pressure.

According to a report published in AHA Journals, blood pressure could be controlled in 50% of patients following 12 weeks of active treatment with losartan. Such findings support continued interest in the medicine as part of hypertension management.

The World Health Organization estimates that approximately 1.3 billion individuals worldwide are living with hypertension, and the number is expected to increase twofold during the forecast period. The growing global disease burden and the need for effective blood pressure management are therefore expected to sustain demand for losartan during the forecast period.

Emerging Therapeutic Applications Creating Market Opportunities

In addition to its established role in hypertension treatment, losartan is being explored for broader therapeutic applications. Companies operating in the market are working toward improving the therapeutic efficacy of combining chemo-immunotherapy with losartan for triple-negative breast cancer.

Market participants and researchers are also exploring the incorporation of losartan into approaches aimed at reducing chronic kidney disease and mortality following acute kidney injury. These areas of investigation could broaden the potential therapeutic relevance of losartan and create new opportunities for companies involved in its development and commercialization.

Another area of focus is increasing awareness regarding appropriate losartan usage in emerging markets. Companies are working to educate populations in regions such as Latin America and the Middle East & Africa regarding the use of losartan, which could contribute to greater market penetration.

At the same time, continued physician supervision remains important because losartan is a prescription medicine. Individuals experiencing unexplained tenderness, muscle pain, or weakness while taking the medicine are advised to consult a doctor.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86266

North America Leads the Losartan Market

North America dominated the global losartan market in 2023 and is expected to maintain its leading position throughout the forecast period. The region's position is supported by increasing awareness regarding the importance of hypertension management and the use of losartan among the U.S. population.

The presence of established healthcare infrastructure and awareness regarding cardiovascular health contributes to the continued demand for antihypertensive medications. Rising attention toward the management of hypertension among older adults is also expected to support the market.

Asia Pacific represents another significant market for losartan. Demand in the region is associated with increasing preference for losartan as a treatment for hypertension among populations in countries such as Singapore and Malaysia.

Awareness campaigns in countries including India and China are also being conducted to increase awareness and expand the consumer base. The combination of a large population base, increasing awareness of hypertension, and growing emphasis on disease management provides opportunities for further market expansion in Asia Pacific.

Competition Landscape

The global losartan market includes several established pharmaceutical companies competing through product development, manufacturing capabilities, distribution networks, and strategic business initiatives. Key players are investing in the development of advanced versions of losartan tablets to strengthen their market positions.

Prominent companies covered in the losartan market include Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Torrent Pharmaceuticals Limited, and Lupin Limited.

Companies are profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments. Competition is also influenced by companies' ability to maintain reliable product availability and expand their presence across major pharmaceutical markets.

The market includes both global pharmaceutical companies and regional manufacturers, creating a competitive environment focused on product development, manufacturing efficiency, geographic expansion, and strengthening distribution networks.

Losartan Market Segmentation

The global losartan market is segmented based on dosage form, application, and distribution channel. By dosage form, the market is divided into tablet, powder, and suspension.

Based on application, the market encompasses hypertension, stroke, diabetic nephropathy, and other applications. Hypertension represents the core therapeutic application of losartan, reflecting the drug's established role in blood pressure management and cardiovascular risk reduction.

By distribution channel, the market is segmented into contract manufacturing, in-house manufacturing, and others. These categories reflect different approaches adopted by companies involved in the production and supply of losartan-based products.

Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Countries covered include the U.S., Canada, Germany, the U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, South Africa, and GCC countries.

Losartan Market Outlook

The global losartan market is expected to maintain steady growth through 2034, supported by the increasing prevalence of hypertension and the rising prefrail geriatric population. Losartan's established role as an angiotensin II receptor blocker and its use in hypertension, stroke risk reduction, and certain kidney-related conditions continue to support demand.

The growing global burden of hypertension remains a particularly important market driver. With approximately 1.3 billion people living with hypertension worldwide, the need for effective blood pressure management is expected to remain significant during the forecast period.

North America is projected to retain its leading position, while Asia Pacific is expected to remain an important market supported by increasing awareness and hypertension-management initiatives in countries such as India and China. Meanwhile, research into additional therapeutic applications and efforts to improve awareness in emerging regions could create further opportunities.

With the market projected to increase from US$ 1.5 Bn in 2023 to US$ 2.3 Bn by 2034 at a CAGR of 4.0%, the losartan industry is positioned for sustained expansion as hypertension management and geriatric healthcare remain key areas of focus.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=86266<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Topical Antibiotics Market

Human Papillomavirus Vaccine Market

Allergy Immunotherapy Market

Protein Therapeutics Market

Next-Generation Immunotherapies Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com